NCIt definition : A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against
the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18),
with potential immunostimulating and antineoplastic activities. Upon administration,
osemitamab specifically targets, binds to and inhibits CLDN18.2 expressed on tumor
cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell
proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of
claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy
tissues is strictly confined to short-lived differentiated epithelial cells of the
gastric mucosa. Osemitamab is produced with reduced fucosylation.;
Semantic type(s)